- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Doptelet, as a thrombopoietin receptor (TPO-R) agonist, has significant therapeutic effects on specific patients with thrombocytopenia. Its effic...
The dosage of Doptelet should be adjusted according to the indications, patient age, and individualized platelet count, including both tablet a...
The use of Doptelet should be implemented according to indications, dosage forms, and patient age differentiation. It should strictly follow co...
The daily dosage of Doptelet should be dynamically adjusted according to indications, platelet count, and patient age. The maximum daily dose f...
Osimertinib is a third-generation EGFR-TKI targeted drug that selectively inhibits EGFR mutations (including T790M) to block tumor signaling pa...
Osimertinib is a third-generation EGFR-TKI targeted drug mainly used for the treatment of EGFR mutation positive non-small cell lung cancer (NS...
Osimertinib is a third-generation EGFR-TKI targeted drug specifically designed for the treatment of EGFR mutation positive non-small cell lung ...
Osimertinib is a third-generation EGFR-TKI targeted drug mainly used for the treatment of EGFR mutation positive non-small cell lung cancer (NS...
Osimertinib, as a third-generation EGFR-TKI targeted drug, covers the full course management of EGFR mutation positive non-small cell lung canc...
The standard usage of Osimertinib is once daily oral administration of 80mg, but individualized adjustments need to be made based on the treatm...
